ArticleJournal of translational medicine2026
Overexpression of PGRMC2 in astrocytes improved cognitive function in a mouse model of Alzheimer's disease by modulating neuroinflammation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveRecent studies have identified persistent immune inflammation as the third core pathological change in Alzheimer’s disease (AD). Progesterone receptor membrane component 2 (PGRMC2) is a member of the membrane-associated progesterone receptor family. This study aimed to investigate the effects of the expression of PGRMC2 in astrocytes in an AD mouse model.
methodsPGRMC2 overexpression in astrocytes was induced in male APPswe/PSEN1dE9 transgenic (AD) mice and C57BL/6J wild-type mice via an adeno-associated virus vector. The Morris water maze and Y-maze tests were used to evaluate spatial learning, spatial memory, and working memory. Cortical thickness and hippocampal volume were evaluated via brain MRI scans. Protein and mRNA levels were analyzed using Western blotting, qPCR, immunohistochemistry, and immunofluorescence techniques.
resultsPGRMC2 expression was significantly elevated in astrocytes in the AD mouse brain tissue. Learning and memory improved, brain atrophy was alleviated, and neuronal loss was reduced, but Aβ1–42 deposition was unaffected. These changes correlated with alterations in NF-κB signaling and shifts in astrocyte phenotypes, including reduced A1 activation and enhanced A2 polarization.
conclusionPGRMC2 overexpression in astrocytes exerts neuroprotective effects on AD mice by altering astrocyte polarization and inflammatory responses; however, the present study does not establish causality in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.